198 related articles for article (PubMed ID: 30088677)
21. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
[TBL] [Abstract][Full Text] [Related]
22. Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats.
Dixit A; Kiran V; Gabani BB; Mohd Z; Trivedi RK; Mullangi R
Biomed Chromatogr; 2020 Apr; 34(4):e4802. PubMed ID: 31998982
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis.
Haverty T; Wyatt DJ; Porter KM; Leubitz A; Banks K; Goodyer P; Hu MY
J Clin Pharmacol; 2021 Jul; 61(7):923-931. PubMed ID: 33355924
[TBL] [Abstract][Full Text] [Related]
24. The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function.
Hruska MW; Adamczyk R; Colston E; Hesney M; Stonier M; Myler H; Bertz R
Br J Clin Pharmacol; 2015 Sep; 80(3):515-24. PubMed ID: 25807956
[TBL] [Abstract][Full Text] [Related]
25. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
Genovese M; Westhovens R; Meuleners L; Van der Aa A; Harrison P; Tasset C; Kavanaugh A
Arthritis Res Ther; 2018 Mar; 20(1):57. PubMed ID: 29566740
[TBL] [Abstract][Full Text] [Related]
26. Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit.
Corrigan B; Feltner DE; Ouellet D; Werth JL; Moton AE; Gibson G
Br J Clin Pharmacol; 2009 Aug; 68(2):174-80. PubMed ID: 19694735
[TBL] [Abstract][Full Text] [Related]
27. Filgotinib for the treatment of rheumatoid arthritis.
Taylor PC; Abdul Azeez M; Kiriakidis S
Expert Opin Investig Drugs; 2017 Oct; 26(10):1181-1187. PubMed ID: 28838249
[TBL] [Abstract][Full Text] [Related]
28. Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib.
Zhuang Y; Sun Q; Jing T; Liu J; Meng H; Cao Y; Qiu Z; Sun J; Li N
Eur J Pharm Sci; 2022 Aug; 175():106211. PubMed ID: 35605911
[TBL] [Abstract][Full Text] [Related]
29. Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".
Srinivas NR
Clin Pharmacokinet; 2015 Dec; 54(12):1293-5. PubMed ID: 26482169
[No Abstract] [Full Text] [Related]
30. Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".
Namour F
Clin Pharmacokinet; 2015 Dec; 54(12):1297-8. PubMed ID: 26482170
[No Abstract] [Full Text] [Related]
31. Filgotinib as rheumatoid arthritis therapy.
Becciolini A; Di Donato E; Santilli D; Lucchini G; Mozzani F; Riva M; Ariani A
Drugs Today (Barc); 2021 Sep; 57(9):543-550. PubMed ID: 34586102
[TBL] [Abstract][Full Text] [Related]
32. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
[TBL] [Abstract][Full Text] [Related]
34. Effect of renal impairment on the pharmacokinetics of exenatide.
Linnebjerg H; Kothare PA; Park S; Mace K; Reddy S; Mitchell M; Lins R
Br J Clin Pharmacol; 2007 Sep; 64(3):317-27. PubMed ID: 17425627
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.
Anderson K; Nelson CH; Gong Q; Alani M; Tarnowski T; Othman AA
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):235-245. PubMed ID: 34468080
[TBL] [Abstract][Full Text] [Related]
37. The pharmacokinetics of pioglitazone in patients with impaired renal function.
Budde K; Neumayer HH; Fritsche L; Sulowicz W; Stompôr T; Eckland D
Br J Clin Pharmacol; 2003 Apr; 55(4):368-74. PubMed ID: 12680885
[TBL] [Abstract][Full Text] [Related]
38. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Tanaka Y; Kavanaugh A; Wicklund J; McInnes IB
Mod Rheumatol; 2022 Jan; 32(1):1-11. PubMed ID: 33740386
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
